Has Michael Lopez received payments from drug or device companies?

Yes. Drug and device makers reported $22,193 in general payments to Michael Lopez across 39 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Michael Lopez did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Michael Lopez come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Michael Lopez

Neurology with Special Qualifications in Child Neurology · Birmingham, ALNPI 1023376746

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $15,948 of the $22,193 with a category attached, or 71.9%. Sarepta Therapeutics, Inc. accounts for 77.1% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2022 at $16,835 and has fallen 96.5% since, to $584 in 2025.

$22,193in general payments, 2019–2025

Across 39 payments — averaging $569.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sarepta Therapeutics, Inc.$17K
Pfizer$2K
PTC Therapeutics, Inc.$2K
Genentech, Inc.$356
Biogen$308
Catalyst Pharmaceuticals, Inc.$273
plus $476 from 4 others

$246,441in research payments, 2019–2025

Across 54 payments — averaging $4563.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Sarepta Therapeutics, Inc.$245K
F. Hoffmann-la Roche AG$2K

What the payments were for

Consulting fees$15,94872%
Travel & lodging$3,82917%
Food & beverage$2,29910%
Education$1171%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sarepta Therapeutics, Inc.	21	$17,118
Pfizer	2	$2,114
PTC Therapeutics, Inc.	1	$1,548
Genentech, Inc.	3	$356
Biogen	5	$308
Catalyst Pharmaceuticals, Inc.	1	$273
Abbott	3	$222
Novartis	1	$125
ITF Therapeutics LLC	1	$65
Novartis Gene Therapies, Inc. (fka Avexis, Inc.)	1	$64

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,193 in reported general payments places this provider in the 85th percentile of 24 neurology with special qualifications in child neurology providers in Alabama.

See all neurology with special qualifications in child neurology providers in Alabama →

Other neurology with special qualifications in child neurology in Birmingham

Alyssa ReddyBirmingham$68K
Alan PercyBirmingham$51K
Elizabeth BebinBirmingham$15K
Amitha AnanthBirmingham$10K
Jan MathisenBirmingham$8K
Monisha GoyalBirmingham$8K
Kathryn LalorBirmingham$3K
Pongkiat KankirawatanaBirmingham$2K
Emily GantzBirmingham$1K
Katherine ThaggardBirmingham$1K

See the full list for Alabama →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →